UMIN-CTR Clinical Trial

Basic information
Public title	A dose-ranging study to evaluate the effects of plant extract on reducing serum triglyceride levels
Acronym	A dose-ranging study to evaluate the effects of plant extract on reducing serum triglyceride levels
Scientific Title	A dose-ranging study to evaluate the effects of plant extract on reducing serum triglyceride levels
Scientific Title:Acronym	A dose-ranging study to evaluate the effects of plant extract on reducing serum triglyceride levels
Region	Japan

Condition
Condition	Healthy adults
Classification by specialty	Not applicable Adult
Classification by malignancy	Others
Genomic information	NO

Objectives
Narrative objectives1	To examine an effective dose of plant extract on reducing serum triglyceride levels
Basic objectives2	Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes	Serum triglyceride levels
Key secondary outcomes	Body fat percentage, Body fat mass, Weight, BMI

Base
Study type	Interventional

Study design
Basic design	Parallel
Randomization	Randomized
Randomization unit	Individual
Blinding	Double blind -all involved are blinded
Control	Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms	3
Purpose of intervention	Prevention
Type of intervention	Food
Interventions/Control_1	Intake of test food contained 100 mg of plant extract for 12 weeks
Interventions/Control_2	Intake of test food contained 200 mg of plant extract for 12 weeks
Interventions/Control_3	Intake of placebo for 12 weeks
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit	20 years-old <=
Age-upper limit	65 years-old >
Gender	Male and Female
Key inclusion criteria	1) Males and females whose age of 20 years or more and less than 65 years 2) Subjects whose serum triglyceride levels are 120 mg/dL or more and 199 mg/dL or less at the screening examination 3) Subjects receiving a sufficient briefing of the objective and content of the present study, fully understanding and agreeing to voluntarily participate in the study and being able to personally sign a written informed consent
Key exclusion criteria	1) Subjects receiving a medical treatment for dyslipidemia 2) Subjects receiving a medical treatment for serious cardio-vascular, hepatic, renal, respiratory, endocrine or metabolic disorders or having a medical history of these disorders 3) Subjects who have the possibility of developing allergic symptoms by the test food 4) Subjects who take Foods for Specified Health Uses or Foods with Function Claims labeled the functions related to lipid metabolism (triglyceride reduction, LDL cholesterol reduction, etc) 5) Subjects who take foods having the effects related to lipid metabolism (triglyceride reduction, LDL cholesterol reduction, etc) 6) Female subjects who are pregnant or lactating, or intending to become pregnant during the study 7) Subjects having blood sample of 200 ml or more taken within 1 month, or 400 ml or more within 3 months prior to the start of the present study (e.g. donated blood) 8) Subjects who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study 9) Subjects deemed unsuitable by the investigator
Target sample size	72

Research contact person
Name of lead principal investigator	1st name Mamiko Middle name Last name Kohno
Organization	Morishita Jintan Co.,Ltd
Division name	Health Care Product Department
Zip code	573-0128
Address	2-11-1, Tsudayamate, Hirakata-shi, Osaka
TEL	072-800-1044
Email	m_kohno@jintan.co.jp

Public contact
Name of contact person	1st name Tomohiro Middle name Last name Sugino
Organization	Soiken Inc.
Division name	R&D Division
Zip code	560-0082
Address	Senri Life Science Center 13F, 1-4-2, Shinsenri-higashimachi, Toyonaka-shi, Osaka
TEL	06-6871-8888
Homepage URL
Email	sugino@soiken.com

Sponsor
Institute	Soiken Inc.
Institute
Department

Funding Source
Organization	Morishita Jintan Co.,Ltd
Organization
Division
Category of Funding Organization	Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization	IRB of Fukuda Clinic
Address	Shin-Osaka brick building 2F, 1-6-1 Miyahara, Yodogawa-ku, Osaka-shi, Osaka
Tel	06-6398-0203
Email	fukudaclinicIRB@gmail.com

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2021 Year 07 Month 05 Day

Related information
URL releasing protocol
Publication of results	Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled	72
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status	Completed
Date of protocol fixation	2021 Year 06 Month 19 Day
Date of IRB	2021 Year 06 Month 19 Day
Anticipated trial start date	2021 Year 08 Month 08 Day
Last follow-up date	2021 Year 11 Month 29 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date	2021 Year 07 Month 05 Day
Last modified on	2022 Year 06 Month 10 Day

Link to view the page
URL(English)	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050978